Document Detail

Ranolazine: a new option in the management of chronic stable angina.
MedLine Citation:
PMID:  18041887     Owner:  NLM     Status:  MEDLINE    
Pharmacotherapy for the management of chronic stable angina has not changed much in the past 10-20 years. Although the use of revascularization has increased, beta-blockers, calcium channel blockers, and long-acting nitrates are still widely used in the management of patients with chronic stable angina. Despite the demonstrated effectiveness of these agents, a number of patients do not achieve the American College of Cardiology-American Heart Association goal of freedom from exertional angina attacks. For the first time in more than a decade, a new agent, ranolazine, is available to assist in controlling exertional angina. Ranolazine has a novel mechanism of action of inhibiting the late sodium current during ventricular depolarization. This mechanism contributes to a reduction in intracellular sodium and, therefore, a reduction in intracellular calcium, reducing ischemic injury. Unlike currently available pharmacotherapy for chronic stable angina, ranolazine does not produce clinically meaningful changes in heart rate or blood pressure. A number of clinical trials have demonstrated the ability of ranolazine to increase exercise tolerance, decrease weekly anginal episodes, and decrease sublingual nitroglycerin consumption for breakthrough angina. Based on the results of these trials, ranolazine recently was approved by the United States Food and Drug Administration for treatment of patients with chronic stable angina. Because of ranolazine's pharmacokinetic and pharmacodynamic profile, pharmacists will have to play a significant role in patient selection and monitoring.
Paul P Dobesh; Toby C Trujillo
Related Documents :
15037897 - Adiponectin in patients with various stages of coronary heart disease - comparison of i...
6492997 - Mechanisms of methacholine-induced coronary vasospasm in an experimental model of varia...
15174217 - Coronary flow reserve after coronary intervention in similar in patients with preserved...
21399557 - Accessory atrioventricular myocardial pathways in mouse heart development: substrate fo...
12846547 - Unexpected accumulation of thallium-201 in bilateral thalamic venous infarction induced...
3444037 - Improved prognosis after coronary thrombolysis with urokinase in acute myocardial infar...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Pharmacotherapy     Volume:  27     ISSN:  0277-0008     ISO Abbreviation:  Pharmacotherapy     Publication Date:  2007 Dec 
Date Detail:
Created Date:  2007-11-28     Completed Date:  2008-02-14     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8111305     Medline TA:  Pharmacotherapy     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1659-76     Citation Subset:  IM    
College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska 68198-6045, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acetanilides / administration & dosage*,  adverse effects,  pharmacokinetics
Angina Pectoris / drug therapy*
Chronic Disease
Delayed-Action Preparations / administration & dosage
Drug Interactions
Enzyme Inhibitors / administration & dosage*,  adverse effects,  pharmacokinetics
Piperazines / administration & dosage*,  adverse effects,  pharmacokinetics
Randomized Controlled Trials as Topic
Reg. No./Substance:
0/Acetanilides; 0/Delayed-Action Preparations; 0/Enzyme Inhibitors; 0/Piperazines; 110445-25-5/ranolazine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Clinical decision support tools: performance of personal digital assistant versus online drug inform...
Next Document:  Traditional management of chronic stable angina.